1 / 32

Infections in the dialysis population: A major communicable disease issue!

Infections in the dialysis population: A major communicable disease issue!. Allan J. Collins, MD, FACP Professor of Medicine University of Minnesota Director, USRDS Coordinating Center. Disclosures.

jane
Download Presentation

Infections in the dialysis population: A major communicable disease issue!

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Infections in the dialysis population: A major communicable disease issue! Allan J. Collins, MD, FACP Professor of Medicine University of Minnesota Director, USRDS Coordinating Center

  2. Disclosures • Institutional research funding: NIH, CDC, National Kidney Foundation, Amgen, Baxter, Sigma Tau, NxStage, Genzyme, BMS, AMAG Pharmaceuticals • Advisory boards in last year: WHO Advisory Panel on NCDs, Kidney Disease Improving Global Outcomes (KDIGO), International Federation of Kidney Foundations (IFKF), • Epidemiology consulting: NxStage, Amgen, Affymax

  3. Infectious complication in dialysis patients: an old yet new communicable disease challenge • Trends in overall mortality show reductions in death rates in years 2-5 after onset of ESRD • Death rates in the first year have not changed in 12 years raising concerns about the underlying morbidity contributing to the early death rates • Cardiovascular and Infectious hospitalizations are the leading cause of morbidity yet little is known about the trends in the first months of dialysis • Here we review the trends in hospitalization rate with particular emphasis on infections as a contributor to morbidity and mortality in the first year of treatment

  4. Mortality rates, by modalityFigure 6.1 (Volume 2) Incident ESRD patients; adjusted for age, gender, race, & primary diagnosis. Incident ESRD patients, 2005, used as reference cohort.

  5. Change in all-cause & cause-specific hospitalization rates, by modalityFigure p.16 (Volume 2) Period prevalent ESRD patients; adjusted for age, gender, race, & primary diagnosis. ESRD patients, 2005, used as reference cohort. Vascular access hospitalizations are “pure” inpatient vascular access events. New vascular access codes for peritoneal dialysis patients appeared in late 1998; therefore, peritoneal dialysis vascular access values are shown as changing since 1999 rather than 1993.

  6. Adjusted admissions for principal diagnoses, by modality Figure 6.5 (Volume 2) Period prevalent ESRD patients; adjusted for age, gender, race, & primary diagnosis. ESRD patients, 2005, used as reference cohort.

  7. Trends in hospitalization surveillance data in the dialysis population • Overall, hospitalization rates have changed little over the last 10-12 years • However, there have been significant changes in the types of hospitalizations with vascular access events transitioning to the outpatient setting with increases in cardiovascular disease and infectious hospitalizations • Hospitalization secondary to pneumonia have increased but have begun to plateau since 2003 • Vascular access infectious event have more than doubled in the last 10 years an area of major concern! • By most standards this would be considered a major communicable disease problem yet the CDC stopped its survey in 2004!!!! • Who and what is responsible for this trend?

  8. Infectious complications in dialysis patients • Infectious hospitalizations have increased in part related to the increases in pneumonia but this trend appears to be reversing with increased evidence of pneumococcal pneumonia vaccinations • Preventive care in the form of influenza vaccinations needs attention and is clearly within the domain of the providers! • Yet other sources of infectious events likely contribute to the increased hospitalization rates

  9. Vascular access use at initiation, 1st outpatient access, 2006 (From Medical Evidence Form 2728)Figure 3.1 (Volume 2) 82% Catheters incident hemodialysis patients, 2006.

  10. First access at initiation, by nephrologist care, 2006Figure 3.4 (Volume 2) incident hemodialysis patients, 2006, with new (revised edition) Medical Evidence forms.

  11. Pre-ESRD nephrologist care, 2006Table 3.a (Volume 2) incident ESRD patients, 2006, with new (revised edition) Medical Evidence forms.

  12. Cumulative probability of catheter placementFigure 1.8 (Volume 2) Medicare: hemodialysis patients who initiate dialysis at age 67 or older during the year specified. Includes those with Medicare as primary payor during the two years prior to initiation & through the first six months of ESRD; pre-ESRD claims used for months prior to initiation date. Medstat (EGHP): patients with first date of regular & continuous dialysis in 2000 or 2005, regardless of age. Only one year of claims prior to the start of dialysis was available for the 2000 cohort.

  13. Cumulative probability of multiple catheter placements determined from service claimsFigure 1.9 (Volume 2) Medicare: hemodialysis patients who initiate dialysis at age 67 or older during the year specified. Includes those with Medicare as primary payor during the two years prior to initiation & through the first six months of ESRD; pre-ESRD claims used for months prior to initiation date. Medstat (EGHP): patients with first date of regular & continuous dialysis in 2000 or 2005, regardless of age. Only one year of claims prior to the start of dialysis was available for the 2000 cohort.

  14. Per person per year vascular access costs, by physician specialty Figure 11.24 (Volume 2) period prevalent hemodialysis patients. Costs determined as the payment amount for each line-level access procedure billed through physician/ supplier claims.

  15. Catheter events & complicationsFigure 5.27 (Volume 2) Prevalent hemodialysis patients age 20 & older, ESRD CPM data; only includes patients who are also in the USRDS database. Year represents the prevalent year & the year the CPM data were collected. Access is that listed as “current” on the CPM data collection form.

  16. Arteriovenous fistula events & complications Figure 5.28 (Volume 2) Prevalent hemodialysis patients age 20 & older, ESRD CPM data; only includes patients who are also in the USRDS database. Year represents the prevalent year & the year the CPM data were collected. Access is that listed as “current” on the CPM data collection form.

  17. Arteriovenous graft events & complications Figure 5.29 (Volume 2) Prevalent hemodialysis patients age 20 & older, ESRD CPM data; only includes patients who are also in the USRDS database. Year represents the prevalent year & the year the CPM data were collected. Access is that listed as “current” on the CPM data collection form.

  18. Access procedures in prevalent hemodialysis patients, by diabetic status Figure hp.13 (Volume 2) Change to cuffed catheters illi illi lla lla Period prevalent hemodialysis patients with or without simple fistulas. Data from physician/supplier claims. Some patients may have more than one access at a given point in time.

  19. Vascular access utilization and infectious complications • Arteriovenous fistula utilization rates have increased during the same time as the Fistula First initiative has been stressed • The Fistula First effort is also associated with reductions in the use of grafts and changes in catheter utilization rates • Infectious complication are highest with catheters and lowest with fistulas but there are similar rates with grafts. • What are the trends in infectious hospitalizations that may relate to vascular access complications

  20. Change in all-cause & cause-specific hospitalization rates, by modality: prevalentFigure p.22 Period prevalent ESRD patients; adjusted for age, gender, race, & primary diagnosis. ESRD patients, 2005, used as reference cohort. Vascular access hospitalizations are “pure” inpatient vascular access events, as described in Appendix A. New vascular access codes for peritoneal dialysis patients appeared in late 1998; therefore, peritoneal dialysis vascular access values are shown as changing since 1999 rather than 1993.

  21. Trends in cardiovascular Hospitalizations in the First Year by months Adjusted for age, gender, race and cause of ESRD Increased cardiovascular hospitalizations Rate per 1,000 Pt Yrs Incident Cohort Year

  22. Trends in Infectious Hospitalization rates in the 1st year by monthAdjusted for age, gender, race and cause of ESRD Increased infectious hospitalizations Rate per 1,000 Pt Yrs Incident Cohort Year

  23. Trends in cardiovascular Hospitalizations in the First Year by months Adjusted for age, gender, race and cause of ESRD Cardiovascular Infections Rate per 1,000 Pt Yrs Incident Cohort Year

  24. Trends in CVD and Infectious Hospitalization rates in the first monthAdjusted for age, gender, race and cause of ESRD Infectious hospitalizations now approach CVD for the 1st time! Rate per 1,000 Pt Yrs Incident Cohort Year

  25. Percent change in hospital admissions from Day 90: 1993 to 2005Incident dialysis patients age 20 and older *Model based adjustment for age, sex, race, cause of ESRD: Interval Poisson regression (ASN 2008 poster)

  26. Percent change in hospital admissions from day 1: 1993 to 2005Incident hemodialysis patients age 65 and older *Model based adjustment for age, sex, race, cause of ESRD: Interval Poisson regression (ASN 2008 poster)

  27. Adjusted admissions for principal diagnoses, by modality Figure 6.5 (Volume 2) *early data noted decline but must be confirmed Period prevalent ESRD patients; adjusted for age, gender, race, & primary diagnosis. ESRD patients, 2005, used as reference cohort.

  28. Adjusted relative risk of mortality after pneumonia: dialysisFigure 6.29 Incident dialysis patients with 90-day rule, Medicare as primary payor, & Part A & B claims, 1992–2000 combined; adjusted for age, gender, race, & primary diagnosis. Reference cohort: patients without corresponding diseases in the first year after ESRD initiation + 90 days. Foley RN, Guo H, Snyder JJ, Gilbertson DT, Collins AJ: Septicemia in the United States Dialysis Population, 1991 to 1999. Journal of the American Society of Nephrology 15 (4): 1038-1045, 2004

  29. Adjusted relative risk of mortality after VA event: dialysis Figure 6.30 Incident dialysis patients with 90-day rule, Medicare as primary payor, & Part A & B claims, 1992–2000 combined; adjusted for age, gender, race, & primary diagnosis. Reference cohort: patients without corresponding diseases in the first year after ESRD initiation + 90 days. Foley RN, Guo H, Snyder JJ, Gilbertson DT, Collins AJ: Septicemia in the United States Dialysis Population, 1991 to 1999. Journal of the American Society of Nephrology 15 (4): 1038-1045, 2004

  30. Trends in Infectious hospitalizations • Infectious hospitalizations have substantially increased over the last 10-13 years • The increase in infectious hospitalizations is more than 4 times greater compared to cardiovascular events in the first months • The increase in infectious hospitalization rates is approaching that of cardiovascular events which is a new finding and they appear to be interrelated • The risk of death after an infectious hospitalization event is significant and is associated with CVD events (The infection/inflammation multiplier hypothesis)!

  31. Conclusions • Death rates in the first months of dialysis are high and need to be addressed • Infectious hospitalizations in the 1st months of dialysis have increased nearly 2 fold • Vascular access infectious hospitalizations are up nearly 3 fold • The consequences of late referral and delayed vascular access planning result in the use of catheters with the accompanying complications and risk of infection and premature death! • The high rates of catheter utilization and associated infectious complications suggest a major effort is needed to reduce catheter utilization (Catheter Last!). • CMS under the QIO scope of work should act to increase early referral and a “Planned Transition” to dialysis consistent with the MIPPA CKD Stage 4 education benefit! • CMS should implement a similar effort for planned transition as was done for Fistula First by engaging health plans, physicians, hospitals and public health infection control officials to reduce the use of catheters!

  32. Acknowledgements • The USRDS Coordinating Center produced the material in this talk based on contributions from the entire staff of • SAS programmers • Biostatistians • Epidemiologist • Physcians • Pharm Ds • Co-investigators • Graphics designers and editors • We would like to thank CMS and the NIH project officers for their support and oversight of the USRDS and the entire kidney disease community for the hard work they do and providing the data!

More Related